Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

N R Waugh; E Cummins; P L Royle; C Clar; M Marien; B Richter; S Philip

doi:10.3310/hta14360

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

N R Waugh, E Cummins, P L Royle, C Clar, M Marien, B Richter, S Philip

Research output: Contribution to journal › Article › peer-review

158 Citations (Scopus)

Abstract

In May 2008, the National Institute for Health and Clinical Excellence (NICE) issued an updated guideline [clinical guideline (CG) 66] for the management of all aspects of type 2 diabetes. This report aims to provide information on new drug developments to support a 'new drugs update' to the 2008 guideline.

Original language	English
Pages (from-to)	1-248
Number of pages	248
Journal	Health Technology Assessment
Volume	14
Issue number	36
DOIs	https://doi.org/10.3310/hta14360
Publication status	Published - Jul 2010

Keywords

adamantane
body weight
cost-benefit analysis
diabetes mellitus, type 2
dipeptidyl-peptidase IV inhibitors
glucagon-like peptide 1
Great Britain
hemoglobin A, glycosylated
humans
hypoglycemic agents
insulin
nitriles
peptides
pyrazines
pyrrolidines
quality of life
randomized controlled trials as topic
state medicine
thiazolidinediones
triazoles
venoms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3310/hta14360

Cite this

@article{4b737244a7ed4b3dac34c0a396200a5b,

title = "Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation",

abstract = "In May 2008, the National Institute for Health and Clinical Excellence (NICE) issued an updated guideline [clinical guideline (CG) 66] for the management of all aspects of type 2 diabetes. This report aims to provide information on new drug developments to support a 'new drugs update' to the 2008 guideline.",

keywords = "adamantane, body weight, cost-benefit analysis, diabetes mellitus, type 2, dipeptidyl-peptidase IV inhibitors, glucagon-like peptide 1, Great Britain, hemoglobin A, glycosylated, humans, hypoglycemic agents, insulin, nitriles, peptides, pyrazines, pyrrolidines, quality of life, randomized controlled trials as topic, state medicine, thiazolidinediones, triazoles, venoms",

author = "Waugh, {N R} and E Cummins and Royle, {P L} and C Clar and M Marien and B Richter and S Philip",

year = "2010",

month = jul,

doi = "10.3310/hta14360",

language = "English",

volume = "14",

pages = "1--248",

journal = "Health Technology Assessment",

issn = "2046-4924",

publisher = "National Co-ordinating Centre for HTA",

number = "36",

}

TY - JOUR

T1 - Newer agents for blood glucose control in type 2 diabetes

T2 - systematic review and economic evaluation

AU - Waugh, N R

AU - Cummins, E

AU - Royle, P L

AU - Clar, C

AU - Marien, M

AU - Richter, B

AU - Philip, S

PY - 2010/7

Y1 - 2010/7

N2 - In May 2008, the National Institute for Health and Clinical Excellence (NICE) issued an updated guideline [clinical guideline (CG) 66] for the management of all aspects of type 2 diabetes. This report aims to provide information on new drug developments to support a 'new drugs update' to the 2008 guideline.

AB - In May 2008, the National Institute for Health and Clinical Excellence (NICE) issued an updated guideline [clinical guideline (CG) 66] for the management of all aspects of type 2 diabetes. This report aims to provide information on new drug developments to support a 'new drugs update' to the 2008 guideline.

KW - adamantane

KW - body weight

KW - cost-benefit analysis

KW - diabetes mellitus, type 2

KW - dipeptidyl-peptidase IV inhibitors

KW - glucagon-like peptide 1

KW - Great Britain

KW - hemoglobin A, glycosylated

KW - humans

KW - hypoglycemic agents

KW - insulin

KW - nitriles

KW - peptides

KW - pyrazines

KW - pyrrolidines

KW - quality of life

KW - randomized controlled trials as topic

KW - state medicine

KW - thiazolidinediones

KW - triazoles

KW - venoms

U2 - 10.3310/hta14360

DO - 10.3310/hta14360

M3 - Article

C2 - 20646668

SN - 2046-4924

VL - 14

SP - 1

EP - 248

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - 36

ER -

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this